Steven Quinlan - Neogen CFO

NEOG Stock  USD 12.02  0.11  0.91%   

CFO

Mr. Steven J. Quinlan, CPA, is the Chief Financial Officer, Vice President of Neogen Corporationrationration. He was named Secretary in October 2011. He is responsible for all internal and external financial reporting for the Company, and also manages the accounting, human resources, information technology, communications and facilities departments. Mr. Quinlan came to the Company following 19 years at Detrex Corporation, the last eight years serving as Vice PresidentFinance, CFO and Treasurer. He was on the audit staff at the public accounting firm Price Waterhouse from 19851989. since 2011.
Age 62
Tenure 13 years
Professional MarksCPA
Address 620 Lesher Place, Lansing, MI, United States, 48912-1595
Phone517 372 9200
Webhttps://www.neogen.com
Quinlan joined Neogen Corporationration in January 2011 as Vice President and Chief Financial Officer. In October 2011, he assumed the position of Secretary. From 1992 to 2010, Mr. Quinlan served in various accounting capacities with Michiganbased Detrex Corporationrationrationration, a publicly held manufacturer of commercial and industrial pipe and specialty chemicals. He served as Vice PresidentFinance, Chief Financial Officer and Treasurer of Detrex from 2002 to 2010, responsible for all finance, accounting and external reporting. Before joining Detrex, he served in accounting and finance related positions at Price Waterhouse and Ford Motor Company .

Neogen Management Efficiency

The Neogen's current Return On Tangible Assets is estimated to increase to -0.0099. The current Return On Capital Employed is estimated to decrease to 0.01. At this time, Neogen's Other Current Assets are most likely to increase significantly in the upcoming years. The Neogen's current Total Current Assets is estimated to increase to about 618.7 M, while Other Assets are projected to decrease to 0.95. Neogen's management efficiency ratios could be used to measure how well Neogen manages its routine affairs as well as how well it operates its assets and liabilities.
Neogen currently holds 906.24 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Neogen has a current ratio of 8.89, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Neogen's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 4 records

CFO Age

Jonathan LyonsSotera Health Co
46
Bryan RiggsbeeMyriad Genetics
53
Brendan BrennanICON PLC
45
Mark StolperRadNet Inc
53
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan. Neogen Cp operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2108 people. Neogen (NEOG) is traded on NASDAQ Exchange in USA. It is located in 620 Lesher Place, Lansing, MI, United States, 48912-1595 and employs 2,917 people. Neogen is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Neogen Leadership Team

Elected by the shareholders, the Neogen's board of directors comprises two types of representatives: Neogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Neogen. The board's role is to monitor Neogen's management team and ensure that shareholders' interests are well served. Neogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Neogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven Quinlan, CFO, Principal Accounting Officer, VP and Secretary
Bill Waelke, Head Relations
John Moylan, Corporate VP
Julie Mann, VP Officer
Amy Rocklin, Chief Secretary
David Naemura, Chief Officer
Sarah Demey, Administrative Manager
Robert Donofrio, Vice President - Food Safety Research and Development
Douglas Jones, COO VP
John Adent, CEO President

Neogen Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Neogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Neogen is a strong investment it is important to analyze Neogen's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neogen's future performance. For an informed investment choice regarding Neogen Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
For more detail on how to invest in Neogen Stock please use our How to Invest in Neogen guide.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neogen. If investors know Neogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.86)
Earnings Share
(0.11)
Revenue Per Share
4.212
Quarterly Revenue Growth
(0.05)
Return On Assets
0.0085
The market value of Neogen is measured differently than its book value, which is the value of Neogen that is recorded on the company's balance sheet. Investors also form their own opinion of Neogen's value that differs from its market value or its book value, called intrinsic value, which is Neogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neogen's market value can be influenced by many factors that don't directly affect Neogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.